Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

News

Blood Clot Drug Totally Ineffective as Post-covid Treatment, Research Finds

-FT https://www.ft.com/content/db1e6c05-b8bb-429e-8cbd-8ea0dde58bf0

byCharles Gross

November 27, 2022

1 minute read

-FT

https://www.ft.com/content/db1e6c05-b8bb-429e-8cbd-8ea0dde58bf0

Keybanc Initiates Coverage On Entegris with Overweight Rating, Announces Price Target of $183

By Benzinga Newsdesk

Today, 7:34 AM

Keybanc analyst Aleksey Yefremov initiates coverage on Entegris (NASDAQ:ENTG) with a Overweight rating and announces Price Target of $183.

ENTG

Why Alibaba And Tesla Rivals Xpeng, Li Auto Are Sliding In Hong Kong Today

By Madhukumar Warrier

Today, 7:34 AM

Shares of U.S.-listed Chinese tech companies traded lower in Hong Kong on Monday, dragging the benchmark Hang Seng Index into negative territory for a third straight day as the Russia-Ukraine crisis showed no signs of abating.

BABA

Insight Enterprises Q1 Adj. EPS $1.81 Beats $1.59 Estimate, Sales $2.65B Beat $2.39B Estimate

By Benzinga Newsdesk

Today, 7:34 AM

Insight Enterprises (NASDAQ:NSIT) reported quarterly earnings of $1.81 per share which beat the analyst consensus estimate of $1.59 by 13.84 percent. This is a 39.23 percent increase over earnings of $1.30 per share from

NSIT

Rite Aid Shares Jump After Upbeat Annual Guidance

By Vandana Singh

Today, 7:34 AM

Rite Aid Corp (NYSE:RAD) has reported Q1 FY23 sales of 6.01 billion, down 2.4% Y/Y, beating the consensus of $5.75…

RAD

Blood Clot Drug Totally Ineffective as Post-covid Treatment, Research Finds

Related Posts

Keybanc Initiates Coverage On Entegris with Overweight Rating, Announces Price Target of $183

Why Alibaba And Tesla Rivals Xpeng, Li Auto Are Sliding In Hong Kong Today

Insight Enterprises Q1 Adj. EPS $1.81 Beats $1.59 Estimate, Sales $2.65B Beat $2.39B Estimate

Rite Aid Shares Jump After Upbeat Annual Guidance